Valiant Laboratories Ltd

  • BSE Code : 543998
  • NSE Symbol : VALIANTLAB
  • ISIN : INE0JWS01017
  • Industry :PHARMACEUTICALS - INDIAN - BULK DRUGS & FORMLN

up-arrow 57.19 0.25(0.44%)

Open Price ()

56.94

Prev. Close ()

56.94

Volume (No’s)

31,798

Market Cap ()

310.61

Low Price ()

54.74

High Price ()

57.80

 

Board Meetings

Start Date End Date Purpose
06-Feb-2026 11-Feb-2026 Valiant Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 inter alia to consider and approve the Financial Results for the Quarter and nine months ended December 31 2025. Audited Standalone and Consolidated Financial Reults for the quarter and nine months ended December 31, 2025. (As Per BSE Announcement Dated on: 11/02/2026)
06-Nov-2025 11-Nov-2025 Valiant Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2025 inter alia to consider and approve the financial results for the quarter and half year ended September 30 2025. Outcome of Board Meeting dated November 11, 2025- Audited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2025. (As Per Bse Announcement dated on 11/11/2025)
05-Aug-2025 08-Aug-2025 Valiant Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2025 inter alia to consider and approve Financial Results (Standalone and Consolidated) for the quarter ended June 30 2025 Outcome of Board Meeting Dated August 08, 2025 - Financial Results for quarter ended June 30, 2025. Outcome of Board Meeting dated August 08, 2025- Financial Results For Quarter Ended June 30, 2025 (As per BSE Announcement Dated on 08.08.2025)
05-Jul-2025 09-Jul-2025 Valiant Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/07/2025 inter alia to consider and approve proposal for raising of funds by way of issue of securities through further public offer rights issue American Depository Receipts/ Global Depository Receipts/ Foreign Currency Convertible Bonds qualified institutions placement debt issue preferential issue or any other method as may be decided and considered appropriate subject to such regulatory/statutory approvals as may be required and matters related and incidental thereto. Considered and approved 1) Fund raising via Rights Issue and 2) Appointment of the Company Secretary and Compliance Officer The board on July 09, 2025, has considered and approved raising of via Rights Issue. (As Per BSE Announcement Dated on 09.07.2025)
14-May-2025 20-May-2025 Valiant Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2025 inter alia to consider and approve Board Meeting Intimation for Considering and Approving Audited Standalone And Consolidated Financial Results for the Quarter and Year Ended March 31 2025. Financial Results for the quarter and year ended March 31, 2025 (As Per BSE Announcement Dated on: 20/05/2025)

Copyright © 2026 Arihant Capital Markets Ltd. All rights Reserved.

Designed, Developed and Content powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)

x
  • QR-CodeNew